Executive Summary
A completed listing and durable access to capital are not the same achievement, and conflating them is one of the most consequential misunderstandings in corporate finance today. Industry analysis of the 2022 small-cap IPO cohort found that 92% of small-cap issuers listed on Nasdaq Capital Market and NYSE American were trading below their offer price roughly a year later, with an average decline of 64.8%, and that more than one-third had already fallen out of compliance with exchange continued-listing requirements. The underwriter's mandate is typically transaction-scoped: price the deal, allocate the shares, exercise the over-allotment option, and close. The company's actual objective — durable, repeatable access to capital at a reasonable cost — is a separate achievement that, for most small-cap issuers, has barely begun on listing day. This article explains why that gap exists, what it costs a company that does not close it, and what a deliberate post-listing capital-markets strategy actually requires.
Introduction
The language around going public reinforces the wrong mental model. "We went public" is treated as a completed accomplishment — the ticker is live, the opening bell has rung, the deal team has moved on to its next mandate. For a narrow segment of large-cap, high-demand offerings, that framing is close enough to true. For the far larger population of small-cap issuers — the companies most relevant to FMP Capital Partners' own client base of growth-stage and cross-border issuers — it is actively misleading.
A company's choice of venue already shapes how much of this risk it inherits — see our related analysis, OTC vs. Nasdaq: Which U.S. Listing Path Is Right for Your Company? — but venue selection alone does not solve it. The underwriter who delivers a company to Nasdaq or NYSE American has, in a real and specific sense, succeeded: the offering priced, the shares allocated, the fee was earned. That same company can still be structurally unable to raise a single additional dollar in the public markets eighteen months later. This is not a contradiction. It is the predictable result of treating a listing as an outcome rather than as the opening move in an ongoing capital-markets relationship.
Background
The scale of the gap is documented, not anecdotal. For the 2022 cohort of small-cap IPOs on Nasdaq Capital Market and NYSE American, industry analysis found average post-listing market capitalization fell from approximately $213 million the day after the offering to approximately $102 million within 28 days, and to roughly $56 million by later measurement — a decline that occurred without any corresponding operating catastrophe in most cases. By the one-year mark, 92% of that cohort traded below its offer price, averaging a 64.8% decline, and more than a third were already non-compliant with the exchange's continued-listing standards, placing them at risk of delisting entirely.
This pattern is not unique to a single vintage year. Separately, a recurring finding across surveys of small- and mid-cap issuers is that a majority — commonly cited around 60% — report that capital markets conditions are actively constraining their growth plans, and that a clear majority of that group points specifically to a lack of trading liquidity as the principal cause, not investor sentiment about their business. Layered on top of this is a fixed cost that does not scale down for smaller issuers: ongoing regulatory and compliance costs for a median U.S. public company run to approximately 4.1% of market capitalization annually, before legal, audit, and investor-relations spend — a burden that a $50 million company absorbs far less comfortably than a $5 billion one.
Put together, these figures describe a specific and common failure mode: a company completes a listing, the underwriter's engagement concludes, trading volume never develops beyond a thin, sporadic level, no research analyst initiates coverage, the share price drifts down on low volume, and the company arrives at the moment it actually needs capital — for growth, for a maturing debt obligation, for an acquisition — holding a security that institutional capital will not touch and that public market mechanics cannot efficiently price.
Strategic Analysis
The underwriter's mandate ends where the company's need begins
This is not a claim that underwriters act in bad faith. An underwriting engagement is priced, staffed, and measured against a specific transaction: the offering itself. Research on underwriting economics and syndicate structure confirms the intuitive point — underwriters who maintain a genuine long-term relationship with an issuer are associated with a larger, more liquid trading market and reduced volatility from block trades after the offering. The inference is straightforward: absent a deliberate structure that extends the relationship past closing, most underwriting engagements are not built to produce that outcome, because that outcome was never what the engagement was scoped or compensated to deliver.
A company that treats the underwriter relationship as concluding at closing — because, contractually, in most cases, it does — has implicitly outsourced its aftermarket capital-markets health to no one. Research coverage, market-making support, and institutional distribution are not automatic byproducts of having completed an IPO. They are the result of deliberate, continued investment that has to be initiated and owned by the company, typically well before the listing itself.
Why the available instruments only work in the order companies rarely expect
A company that needs to raise capital after listing has several real, well-established instruments available. What is rarely made explicit is that each one requires a precondition the previous one does not, and that arriving unprepared collapses the choice to whichever instrument requires the least market strength — which also happens to be the most expensive one.
Follow-on offering. A traditional underwritten public offering of additional shares. This works well, and can even signal strength to the market, when the share price sits close to a credible market level and real institutional demand exists. It requires exactly the aftermarket health — price stability, analyst attention, an institutional shareholder base — that most small-cap issuers never developed.
Shelf registration and at-the-market (ATM) programs. A shelf registration allows a company to pre-register a block of securities and issue them over time; an ATM program then lets the company sell small amounts of stock incrementally into the existing trading market through a designated broker-dealer, at prevailing prices, without a roadshow. An ATM's practical usefulness is directly proportional to the depth of the market it is selling into — it is close to worthless without sustained trading volume to absorb the sales without moving the price against the issuer.
Rights issue. An offer to existing shareholders to buy additional shares, typically at a discount, in proportion to their current holding. This raises capital without necessarily requiring new institutional demand, but it depends on the existing shareholder base having the capacity and willingness to fund a discounted follow-on investment — not a given for a retail-heavy or thinly capitalized base.
PIPE (private investment in public equity). A privately negotiated placement of securities to a small number of investors, typically executed under Regulation D or Section 4(a)(2). PIPEs offer real speed and flexibility, which is precisely why they are the instrument a company without aftermarket health ends up defaulting to. That speed is priced: PIPE terms are structurally more dilutive and more investor-friendly than a marketed offering, because the investor is compensating for the liquidity and pricing risk the issuer's own market has failed to absorb.
The pattern across all four instruments is the same: each one's cost and availability is a function of aftermarket health that was either built deliberately in the months after listing, or was not. A company that skips that work does not lose access to capital entirely — it loses access to the cheaper forms of it, and is left negotiating from the weakest possible position at exactly the moment it can least afford to.
Practical Considerations
This groundwork begins well before the offering itself — see our IPO Readiness Checklist: 20 Critical Steps Before Going Public for the pre-listing foundation this section builds on. A post-listing capital-markets strategy is not a set of tactics to apply after the share price has already deteriorated — by that point, the options have already narrowed. It is a plan built, staffed, and budgeted for before the listing itself, alongside the offering process, not after it. In practice this means:
Investor relations as a function, not a document. A continuously maintained investor narrative, disclosure cadence, and direct line to both existing and prospective institutional holders — not a static investor deck updated once a year.
A deliberate research-coverage strategy. Sell-side research coverage does not occur by default for a small-cap issuer; it typically requires a company to actively cultivate the relationships and provide the access that make an analyst's coverage initiation commercially worthwhile to their firm.
Market-making and liquidity provisioning discussed at the offering stage, not after. Which market makers will support the security, and on what terms, is a question worth resolving during the listing process — reconstructing that support after the fact, once volume has already thinned out, is materially harder.
A realistic view of the shareholder base being built at IPO. A retail-heavy allocation is not disqualifying, but it changes which of the four instruments above will actually be available later, and that should inform how the initial offering itself is marketed and allocated.
Compliance cost budgeted as a permanent, non-negotiable operating expense — approximately 4.1% of market capitalization annually for a median public company — rather than treated as a one-time cost of the IPO process itself.
Key Risks
A company that lists without this groundwork faces a specific, compounding set of risks, not a single point of failure:
Delisting risk. More than a third of the analyzed 2022 small-cap cohort had already fallen out of compliance with continued-listing standards within roughly a year — a company does not need to fail commercially to face this outcome; declining share price and thinning market capitalization can trigger it on their own.
Forced reliance on the most dilutive instrument at the worst possible time. A capital need that arises after aftermarket health has already deteriorated is very often met, if at all, through a PIPE priced on terms that reflect the company's weak negotiating position — compounding shareholder dilution precisely when the company can least afford it.
Reputational cost with institutional capital. A depressed, illiquid security carries a market memory. Rebuilding institutional credibility after a poorly-supported aftermarket is a materially harder and slower undertaking than building it correctly the first time.
Compliance costs that do not scale down. A shrinking market capitalization does not bring a corresponding reduction in the fixed costs of being a public company, compressing the margin for error further at exactly the point resources are most constrained.
Recommendations
FMP Capital Partners recommends that any company evaluating a U.S. listing build its post-listing capital-markets plan as an integral part of the listing process itself, not as a follow-on project once the ticker is live:
Treat the underwriter relationship, research-coverage strategy, and market-making arrangements as decisions to be made during the offering process, with the aftermarket outcome specified as an explicit objective — not assumed as an automatic result of a successful pricing.
Build the investor-relations function before listing, not after the first quarterly report is due.
Model which of the four post-listing capital instruments the anticipated shareholder base and trading profile will actually make available, and size the initial offering and allocation strategy with that in mind.
Budget ongoing compliance and investor-relations costs as a permanent line item from year one, sized against a realistic view of post-listing market capitalization — not the valuation assumed at pricing.
Revisit the capital-markets plan at defined intervals after listing, rather than only when a capital need becomes urgent — by the time a raise is urgent, the cheaper instruments are often no longer available.
Frequently Asked Questions
Does an underwriter's responsibility include supporting the stock after the IPO?
Not automatically, and not by default contractual scope. An underwriting engagement is typically priced and staffed around the offering itself — pricing, allocation, and closing. Continued aftermarket support, such as research coverage or market-making, is associated with underwriters who maintain a genuine ongoing relationship with the issuer, but that continuation has to be deliberately structured and, in practice, actively pursued by the company. It is not a service most engagements are scoped or compensated to provide by default.
What is the practical difference between an ATM offering and a follow-on offering?
A follow-on offering is a traditional, marketed, underwritten transaction — typically priced at a discount to the prevailing market price and executed in a single event, usually accompanied by investor outreach. An at-the-market (ATM) program instead allows a company to sell shares incrementally, over time, directly into the existing trading market at prevailing prices through a designated broker-dealer, without a roadshow. A follow-on can signal strength when demand is genuinely present; an ATM's usefulness depends entirely on the depth and consistency of the trading volume it is selling into.
Why do PIPE transactions typically carry worse terms than a marketed offering?
A PIPE investor is providing capital and liquidity that the company's own public market has failed to supply, and is compensated for the additional risk and illiquidity they are absorbing on the company's behalf. This is why PIPE terms are structurally more dilutive and more investor-friendly than what a company could typically achieve through a follow-on offering or ATM program executed from a position of aftermarket strength.
How soon after an IPO can a company realistically raise additional capital?
There is no fixed timeline set by regulation alone; the real constraint is market readiness, not a waiting period. A company with genuine aftermarket health — price stability, institutional demand, analyst attention — can in principle access a follow-on or ATM program within months of listing. A company without that groundwork may find every instrument effectively unavailable on acceptable terms regardless of how much time has passed, which is precisely the trap this article describes.
What actually causes a newly listed small-cap stock to become illiquid?
Illiquidity in this context is rarely caused by a single event. It typically compounds from the absence of active market-making support, the lack of initiated research coverage, a retail-heavy shareholder base without institutional anchor investors, and a declining share price that itself discourages further institutional interest — each of which reinforces the others once the pattern begins, which is why addressing it proactively before listing is materially easier than correcting it afterward.
Conclusion
The underwriter who prices the deal and the company that needs durable capital access are, in the moment the listing closes, both correct that something has been achieved — but they are not describing the same achievement. Ninety-two percent of a recent small-cap IPO cohort trading below offer price within a year, and more than a third at delisting risk, are not primarily stories of failed businesses. They are, in large part, the visible outcome of treating a listing as a finish line rather than as the first move in a capital-markets strategy that has to be built, staffed, and funded deliberately. The companies that avoid this outcome are not the ones with the best listing-day headlines — they are the ones that planned for the years after listing day with the same rigor they applied to the offering itself. For companies for whom a public listing is not yet the right instrument at all, our analysis of private capital-raising alternatives to going public is a useful companion starting point.
About FMP Capital Partners
Planning to access the U.S. capital markets? FMP Capital Partners advises growth companies on Nasdaq listings, OTC Markets, SEC readiness, capital raising, and cross-border transactions. Contact our advisory team for a confidential discussion regarding your capital markets strategy.